Background
Data are limited on weight gain after switching from second-line boosted PI-based regimens to B/F/TAF in low and middle-income countries (LMICs). We assessed weight in a clinical trial that compared continuing boosted PI + NRTIs vs. B/F/TAF during a period of severe civil unrest in Haiti.
Methods
The parent study was a prospective, open-label trial conducted at GHESKIO in Port-au-Prince, Haiti. Adults (³18 years) with viral suppression on second-line PI/r-based ART were randomized to continue their current regimen vs. switch to B/F/TAF. In this secondary analysis, we assessed weight gain and food insecurity.
Results
Between October 2020 and April 2023, 301 participants were enrolled and randomized (B/F/TAF: 153; bPI: 148). Median age was 49 years (IQR 42, 56), 173 (57%) were women, the median BMI was 23.3 kg/m2 (IQR 20.8-27.1) and 28 (9%) had BMI <18.5. At enrollment, 175 (60%) were taking lopinavir/r and 115 (40%) atazanavir/r; 226 (78%) were taking tenofovir disoproxil fumarate, 51 (18%) zidovudine, and 13 (4%) abacavir; all were taking lamivudine or emtricitabine. At Week 48, the median change in weight was +1.7kg (IQR: -0.6, +5.1) in the B/F/TAF and -1.1kg (IQR: -2.9, +1.1) in the bPI group (p<0.001). In the B/F/TAF group, median weight gain was higher in females than males (+2.9 kg vs. +0.6 kg; p<0.001), and 21.7% of females vs. 8.2% of males (p<0.001) gained ³10% body weight (Table 1). In contrast, the bPI group had median weight loss of -0.8kg in females and -1.7 kg in males. In the total cohort, the proportion of participants with severe food insecurity increased from 40.1% at enrollment to 49.2% at 48 weeks (p<0.001). There was no difference in the proportion with severe food insecurity at enrollment or 48 weeks by group.
Conclusions
Weight gain was common among females who switched from PI/r-based regimens (78% included TDF) to B/F/TAF, in the context of high rates of food insecurity. This is consistent with findings of similar drug switches in other settings. In contrast, we observed weight loss in the standard of care group, which may have different clinical implications in settings with high rates of food insecurity. Understanding the implications of weight gain after stopping TDF is essential to guide global policies on TDF-sparing regimens.
Table or Figure
![]()